New drug cocktail targets Hard-to-Treat brain cancers
NCT ID NCT01107522
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase study tests an experimental drug called CTO, alone or combined with standard chemotherapy (Temodar) and radiation, in people with advanced solid tumors or glioblastoma (a type of brain cancer). The main goal is to find the safest dose and check for side effects. About 100 participants will be enrolled across three treatment groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carboxyamidotriazole orotate (CTO) and temozolomide (Temodar)
What this could lead to
If successful, this could point toward a new combination treatment for glioblastoma and other advanced solid tumors.
What could go wrong
This is a very early Phase 1 trial with only 100 participants, focused on safety and dosing. It is too soon to know if the drug combination will effectively shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10017, United States
-
New York University
New York, New York, 10016, United States
-
Oregon Health and Sciences University
Portland, Oregon, 97239, United States
-
Providence Cancer Center
Portland, Oregon, 97213, United States